These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 33036377)

  • 21. Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis.
    Kate S; Chougule A; Joshi A; Noronha V; Patil V; Dusane R; Solanki L; Tiwrekar P; Trivedi V; Prabhash K
    Lung Cancer (Auckl); 2019; 10():1-10. PubMed ID: 30774491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure.
    Yoshida T; Kuroda H; Oya Y; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Lung Cancer; 2017 Jul; 109():89-91. PubMed ID: 28577956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
    Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
    BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.
    Hao Y; Xu M; Jin J; Si J; Xu C; Song Z
    Cancer Med; 2023 Aug; 12(15):15903-15911. PubMed ID: 37306192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring
    Tanaka K; Nosaki K; Otsubo K; Azuma K; Sakata S; Ouchi H; Morinaga R; Wataya H; Fujii A; Nakagaki N; Tsuruta N; Takeshita M; Iwama E; Harada T; Nakanishi Y; Okamoto I
    Oncotarget; 2017 Sep; 8(40):68123-68130. PubMed ID: 28978102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon
    Tan J; Hu C; Deng P; Wan R; Cao L; Li M; Yang H; Gu Q; An J; Jiang J
    Front Oncol; 2021; 11():646577. PubMed ID: 34513661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
    J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer.
    Huang AC; Huang CH; Ju JS; Chiu TH; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
    Ther Adv Med Oncol; 2021; 13():17588359211035710. PubMed ID: 34377157
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Xu H; Yang G; Liu R; Yang Y; Li W; Li J; Hao X; Xing P; Wang Y
    Front Pharmacol; 2022; 13():976731. PubMed ID: 36188595
    [No Abstract]   [Full Text] [Related]  

  • 34. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
    Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.
    Borgeaud M; Parikh K; Banna GL; Kim F; Olivier T; Le X; Addeo A
    J Thorac Oncol; 2024 Jul; 19(7):973-983. PubMed ID: 38499147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment Patterns, Testing Practices, and Outcomes in Patients with
    Pluzanski A; Bryl M; Chmielewska I; Czyzewicz G; Luboch-Kowal J; Wrona A; Samborska A; Krzakowski M
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.
    Wu JY; Shih JY
    Onco Targets Ther; 2016; 9():6137-6145. PubMed ID: 27785061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.